Diabetologie und Stoffwechsel 2025; 20(S 01): S44-S45 DOI: 10.1055/s-0045-1807442
Abstracts | DDG 2025
Poster
Posterwalk 5: Diabeteskomplikationen I Niere I Fuß
Clinical Factors Associated with Insulin Regression When Adding Tirzepatide in Basal
Insulin–Treated Type 2 Diabetes
Authors
C Wysham
1
Rockwood Clinic, Department of Diabetes and Endocrinology, Spokane, United States
J Rosenstock
2
Velocity Clinical Research at Medical City, Senior Scientific Advisor Velocity Clinical
Research; Director Velocity Clinic at Medical City Dallas; Clinical Professor of Medicine,
Univ. of Texas Southwestern Medical Center, Dallas, Texas, United States
S Tofé
3
University Hospital Son Espases, Department of Endocrinology and Nutrition, Palma,
Spain
V Thieu
4
Eli Lilly and Company, Cardiometabolic Health, Indianapolis, United States
J Kiljanski
4
Eli Lilly and Company, Cardiometabolic Health, Indianapolis, United States
C Lee
5
Eli Lilly and Company, Global Medical Affairs Obesity/NILEX, Indianapolis, United
States
H Wang
6
TechData Service Company LLC, TechData Service Company LLC, Philadelphia, United States
H Patel
7
Eli Lilly and Company, Type 2 Diabetes Development, Indianapolis, United States
